A prospective non-interventional study to evaluate the effect of Triptorelin Embonate (Diphereline (TM) 11.25mg) on lower urinary tract symptoms (LUTS) in Australian prostate cancer patients
Phase of Trial: Phase IV
Latest Information Update: 21 Jun 2016
At a glance
- Drugs Triptorelin (Primary)
- Indications Lower urinary tract symptoms; Prostate cancer
- Focus Therapeutic Use
- Sponsors Ipsen
- 08 Jun 2016 Status changed from active, no longer recruiting to completed.
- 27 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry record.
- 15 Dec 2010 New trial record